Antitumor activity of dextran derivatives immobilizing platinum complex (II)

Abstract

The in vivo antitumor activity and toxicity of a newly synthesized polymeric prodrug of cisplatin was investigated and also compared with plain cisplatin. The prodrug included a dicarboxymethyl-dextran conjugate of cisplatin (DCM-Dex/CDDP). DCM-Dex/CDDP was i.v. injected in mice bearing s.c. Colon 26 mouse colon cancer cells. The tissue distribution of platinum was thereafter determined by flameless atomic absorption spectrophotometry. The platinic concentration of the organs showed a high rate of retention at 24 h after injection in the DCM-Dex/CDDP-treated mice. No biochemical or hematologically adverse effects were observed. In addition, DCM-Dex/CDDP showed a significantly higher antitumor activity than cisplatin alone. These results indicate that DCM-Dex/CDDP may therefore be a potentially effective cancer chemotherapy.

Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer

“…Due to its biocompatibility and immunoneutrality, dextran is extensively employed as a bioinert material in biomedical science, tissue engineering, and drug delivery systems. [1][2][3][4][5] In addition, dextran has confluent moieties for chemical conjugation, ie, a hydroxyl group exists in each glucose unit. Therefore, dextran is frequently investigated for use as a drug carrier system for anticancer drugs, antidiabetic agents, antibiotics, peptides, and enzymes.…”

Dextran-b-poly(L-histidine) copolymer nanoparticles for pH-responsive drug delivery to tumor cells

“…Because dextran is biocompatible, biodegradable, and immunoneutral, it is extensively employed for modification of bioactive materials. 21,[25][26][27][28] Further, dextran has the potential to avoid unwanted protein or cellular absorption and to increase the blood circulation time, depending on molecular weight. [29][30][31] Dextran has also been used to deliver anticancer agents in systemic drug delivery systems.…”

Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs

“…They reported that the cytotoxicity of the MTXester-dextran and MTX-amide-dextran were equivalent to unmodified MTX however the conjugation resulted in shifting of dose-response curve to a lower dose (156). Also, Ichinose et alsynthesized dicarboxymethyl dextran conjugate of cisplatin by immobilizing cisplatin to dextran polymer chain through six-membered chelating coordinate bond which exhibited remarkably longer half-life and better tumour inhibition activity than pure cisplatin in the colon (157). Charged dextran derivatives such as carboxymethyl dextran, dextran sulphate and diethylaminoethyl dextran can also form complexes with several small bioactive chemical entities due their huge numbers of hydroxyl groups available for complexation and can be extensively explored as drug carrier systems because they are biocompatible, biodegradable, non toxic, non immunogenic and non antigenic.…”